Wandercraft Initiates Landmark Trial for Hands-Free Personal Exoskeleton in SCI Patients
Key Insights
Wandercraft has launched a groundbreaking clinical trial for its Personal Exoskeleton technology, designed to provide hands-free walking independence for individuals with severe mobility impairments.
The trial is being conducted at the James J. Peters VA Medical Center in the Bronx, with plans to expand to the Kessler Institute for Rehabilitation in New Jersey.
Building on their FDA-cleared Atalante X platform, the new Personal Exoskeleton system adapts to users' movements in real-time and enables walking across various surfaces without crutches or walkers.
Wandercraft, a pioneer in mobility assistance technology, has commenced a significant clinical trial to evaluate its innovative Personal Exoskeleton system, marking a potential breakthrough in mobility solutions for individuals with severe walking impairments.
The trial, initiated at the James J. Peters VA Medical Center in the Bronx, New York, aims to assess the safety and effectiveness of the company's latest exoskeleton technology in patients with spinal cord injuries (search) (SCI). The study is set to expand to the Kessler Institute for Rehabilitation in West Orange, New Jersey.
Advanced Features and Capabilities
The Personal Exoskeleton represents a significant advancement in assistive technology, featuring self-balancing capabilities and real-time adaptation to user movements. The system enables walking across diverse surfaces, including carpet, concrete, and tile, without requiring crutches or walkers for support - a notable improvement over existing mobility solutions.
This development builds upon Wandercraft's existing FDA-cleared Atalante X exoskeleton, which has already demonstrated success in helping individuals with SCIs regain the ability to stand and walk. The new system aims to provide more comprehensive mobility support, including standing, walking, bending, and reaching capabilities.
Clinical Impact and Future Implications
"The launch of this trial is a major milestone in our journey to redefine what mobility technology can achieve," stated Matthieu Masselin, CEO of Wandercraft. "We've seen the profound impact of our exoskeletons in rehabilitation centers, and now we are thrilled to explore how the Personal Exoskeleton could represent a significant leap forward in mobility and walking independence."
The technology has already garnered attention in high-profile settings, having been showcased during last year's Olympic torch-lighting ceremony. This practical demonstration highlighted the system's potential to transform daily living for individuals with mobility impairments.
Beyond basic mobility assistance, the Personal Exoskeleton is designed to restore a more natural walking experience to users' everyday lives. This approach reflects a broader understanding of mobility assistance, focusing not just on functional movement but on improving overall quality of life for individuals with severe walking impairments.